People who inject drugs (PWID) are at risk for HIV infection from both sexual- as well as injection-related causes. What can clinicians do to reduce the incidence of infection and improve their patients’ health? In this issue, Dr. Jessica Taylor from The Boston University School of Medicine and Boston Medical Center takes us into the clinic to explain how current evidence-based strategies can increase the uptake of HIV pre-exposure prophylaxis in this vulnerable population.
“U=U” — an Undetectable HIV viral load means Untransmittable HIV virus. In her recent eHIV Newsletter Issue (Vol. 4; No. 11), Dr. Jill Blumenthal from the Division of Infectious Diseases and Global Public Health at the University of California San Diego analyzed the current evidence strongly supporting this concept. In this Podcast, she discusses “U=U” from the clinical perspective, and models how it can help promote patient safety.
PrEP — pre-exposure prophylaxis to prevent HIV transmission — is safe, it’s effective, and it’s significantly underused in the U.S. One key barrier to increased PrEP use is a lack of awareness and acceptance among the patient populations most at-risk for new HIV infection.
In this podcast, Dr. Douglas Krakower from Harvard Medical School takes us into the exam room to translate the new information in his Newsletter Issue into clinical practice.
Allison Agwu, Associate Professor of Pediatrics and Infectious Diseases, covers the important topic of Treating Youth and Young Adults with HIV Infection in the format of case-study scenarios for the clinical practice.
Dr. Kenneth H. Mayer from Harvard discusses the important issues related to Pre-Exposure Prophylaxis (PrEP) in HIV-uninfected individuals at high-risk and reviews the results of several key studies that evaluated the use of PrEP.